Alkem Laboratories announced that the Board of Directors of the Company at its meeting held on 9 February 2024, has recommended a Interim dividend of Rs.35 per share (i.e.1750%), subject to the approval of the shareholders.Powered by Capital Market - Live News

Net profit of Alkem Laboratories rose 30.84% to Rs 594.96 crore in the quarter ended December 2023 as against Rs 454.71 crore during the previous quarter ended December 2022. Sales rose 9.31% to Rs 3323.87 crore in the quarter ended December 2023 as against Rs 3040.91 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales3323.873040.91 9 OPM %21.2919.70 - PBDT775.77617.33 26 PBT706.21538.89 31 NP594.96454.71 31 Powered by Capital Market - Live News

Alkem Laboratories will hold a meeting of the Board of Directors of the Company on 9 February 2024.Powered by Capital Market - Live News

Alkem Laboratories has appointed Nitin Agrawal as the Chief Financial Officer of the Company w.e.f. 01 February 2024. Rajesh Dubey, present Chief Financial Officer of the Company has contributed significantly to the Company`s growth through his expertise in Finance and Accounting. Rajesh Dubey will retire from the Company on 15 March 2024Powered by Capital Market - Live News

Net profit of Alkem Laboratories rose 87.56% to Rs 620.52 crore in the quarter ended September 2023 as against Rs 330.84 crore during the previous quarter ended September 2022. Sales rose 11.72% to Rs 3440.17 crore in the quarter ended September 2023 as against Rs 3079.37 crore during the previous quarter ended September 2022. ParticularsQuarter Ended�Sep. 2023Sep. 2022% Var. Sales3440.173079.37 12 OPM %21.7114.74 - PBDT779.60479.73 63 PBT705.70402.33 75 NP620.52330.84 88 Powered by Capital Market - Live News